Housheng Hansen

Dec 8, 2023 | genomebiology.biomedcentral.com | Housheng Hansen |Cheeloo College |Biocenter Oulu

To examine the relationship between CpG methylation and CTCF binding, we gathered a total of 95,887 CTCF binding sites from 26 human cell lines or tissues (Additional file 5: Fig. S1A), along with the methylation levels of 1,188,556 CpG dinucleotides located on these CTCF binding sites, from the ENCODE portal [12].

Aug 24, 2023 | frontiersin.org | Housheng Hansen |Yafeng Ma |Dimple Chakravarty |Annika Fendler

MainTreatment options for metastatic lesions of prostate cancer (PCa) are limited, and resistance to androgen signalling inhibitors (ASI) is ultimately inevitable (1–3). Detecting aggressive disease while it is still manageable and understanding the underlying biology are clinical imperatives. The standard invasive tissue biopsy procedure for PCa diagnosis poses a risk to the patient (4), is limited in the early stages of disease (5), and is impractical for longitudinal disease monitoring.

Jul 4, 2023 | academic.oup.com | Ontario Canada |Housheng Hansen

Cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) has emerged as a promising liquid biopsy technology to detect cancers and monitor treatments. While several bioinformatics tools for DNA methylation analysis have been adapted for cfMeDIP-seq data, an end-to-end pipeline and quality control framework specifically for this data type is still lacking.

Apr 30, 2023 | paperity.org | Housheng Hansen

Nature Communications, Apr 2023 This is a preview of a remote PDF: https://www.nature.com/articles/s41467-023-37544-3.pdf Wei, Zhao, Wang, Song, Xu, Yaning, Wang, Wenzheng, Soares, Fraser, Ahmed, Musaddeque, Su, Ping, Wang, Tingting, Orouji, Elias, Xu, Xin, Zeng, Yong, Chen, Sujun, Liu, Xiaoyu, Jia, Tianwei, Liu, Zhaojian, Du, Lutao, Wang, Yunshan, Chen, Shaoyong, Wang, Chuanxin, He, Housheng Hansen, Guo, Haiyang.

Mar 6, 2023 | aacrjournals.org | Housheng Hansen

The lysine demethylase LSD1 (also called KDM1A) plays important roles in promoting multiple malignancies including both hematologic cancers and solid tumors. LSD1 targets histone and non-histone proteins and can function as a transcriptional corepressor and coactivator. LSD1 has been reported to act as a coactivator of androgen receptor (AR) in prostate cancer (PCa) and to regulate the AR cistrome via demethylation of its pioneer factor FOXA1.